Boston Scientific has purchased technology for treating symptomatic benign prostatic hyperplasia (BPH) from Celsion Corporation (following approval of the acquisition by Celsion stockholders at the company's annual meeting in June 2007. The purchase consists primarily of the Prolieve Thermodilatation System, which Boston Scientific has exclusively distributed since 2004.
Prolieve System is a non-surgical, less invasive, microwave-based treatment for symptomatic BPH which is routinely performed in the physician's office. The Prolieve System's transurethral catheter uses microwave heating to reduce the enlarged prostate tissue and improve urine flow. The catheter also includes a dilatation balloon, a feature not available in other currently available microwave technologies for BPH. The balloon is used to dilate, or open, the prostatic urethra during the microwave treatment.
"The acquisition of the Prolieve System results from the successful four-year relationship between Boston Scientific and Celsion," said Eric Goorno, President of Boston Scientific's Urology/Gynecology business. "This purchase demonstrates Boston Scientific's continued commitment to improving treatment options for those suffering from urologic conditions, including BPH."
